Angiostatin selectively inhibits signaling by hepatocyte growth factor in endothelial and smooth muscle cells

Blood

Volumn 101, Issue 5, 2003, Pages 1857-1863

  Wajih, Nadeem ^a   Sane, David C ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOSTATIN; IODINE 125; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE B; SCATTER FACTOR; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; SMOOTH MUSCLE FIBER; TUMOR CELL LINE; TUMOR GROWTH; VASCULAR SMOOTH MUSCLE;

EID: 0037372436     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-02-0582     Document Type: Article

References (41)

1. Folkman J, Browder T, Palmbrad J. Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost. 2001;86:23-33.
2. Folkman J. Tumor angiogenesis. In: Bast RC Jr, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E III, eds. Cancer Medicine, 5th ed. Hamilton, Ontario, Canada: BC Decker; 2000:132-152.
3. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994;79:315-328.
4. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med. 1996;2:689-692.
5. Kisker O, Onizuka S, Banyard J, et al. Generation of multiple angiogenesis inhibitors by human pancreatic cancer. Cancer Res. 2001;61:7298-7304.
6. Gately S, Twardowski P, Stack MS, et al. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res. 1996;56:4887-4890.
7. Stathakis P, Fitzgerald M, Metthias LJ, Chesterman CN, Hogg PJ. Generation of angiostatin by reduction and proteolysis of plasmin. J Biol Chem. 1997;272:20641-20645.
8. Gately S, Twardowski P, Stack MS, et al. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci U S A. 1997;94:10868-10872.
9. Walter JJ, Sane DC. Angiostatin binds to smooth muscle cell in the coronary artery and inhibits smooth muscle cell proliferation and migration in vitro. Arterioscler Thromb Vasc Biol. 1999;19:2041-2048.
10. Griscelli F, Li H, Bennaceur-Griscelli A, et al. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci U S A. 1998;95:6367-6372.
11. Claesson-Welsh L, Welsh M, Ito N, et al. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci U S A. 1998;95:5579-5583.
12. Ito H, Rovira II, Bloom ML, et al. Endothelial progenitor cells as putative targets for angiostatin. Cancer Res. 1999;59:5875-5877.
13. Moser TL, Kenan DJ, Ashley TA, et al. Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc Natl Acad Sci U S A. 2001;98:6656-6661.
14. Moser TL, Stack MS, Asplin I, et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci U S A. 1999;96:2811-2816.
15. 3 in endothelial cells. J Biol Chem. 2001;276:39562-39568.
16. Stack MS, Gately S, Bafetti LM, Enghild JJ, Soff GA. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochem J. 1999;340:77-84.
17. Troyanovsky B, Levchenko T, Månsson G, Matvijenko O, Holmgren L. Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol. 2001;152:1247-1254.
18. Cao Y, Ji RW, Davidson D, Schaller J, Martinas M, Folkman J. Kringle domains of human angiostatin. J Biol Chem. 1996;271:29461-29467.
19. Nakamura T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989;342:440-443.
20. Naldini L, Weidner KM, Vigna E, et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J. 1991;10:2867-2878.
21. Galvani AP, Cristiani C, Carpinelli P, Landonio A, Bertolero F. Suramin modulates cellular levels of hepatocyte growth factor receptor by inducing shedding of a soluble form. Biochem Pharmacol. 1995;50:959-966.
22. Kuba K, Matsumoto K, Date K, Shimura H, Tanaka M, Nakamura T. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res. 2000;60:6737-6743.
23. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157-1164.
24. Gutheil JC, Campbell TN, Pierce PR, et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res. 2000;6:3056-3061.
25. Nakagami H, Morishita R, Yamamoto K, et al. Mitogenic and antiapoptotic actions of hepatocyte growth factor through ERK, STAT3, and Akt in endothelial cells. Hypertension. 2001;37:581-586.
26. Kohn AD, Summers SA, Bimbaum MJ, et al. Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulated glucose uptake and glucose transporter 4 translocation. J Biol Chem. 1996;271:31372-31378.
27. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399:601-605.
28. Coffer PJ, Jin J, Woodgett JR. Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochemical J. 1998;335:1-13.
29. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231-241.
30. Del Peso L, Gonzalez-Garcia M, Page C, Herrara R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science. 1997;278:687-689.
31. Cardone MH, Roy N, Stannicke HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998;282:1318-1321.
32. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell. 1999;96:857-868.
33. 3 integrins that elevates bcl-2 transcription. J Biol Chem. 2001;276:27757-27763.
34. Mirza AM, Kohn AD, Roth RA, McMahon M. Oncogenic transformation of cells by a conditionally active form of the protein kinase Akt/PKB, Cell Growth Differ. 2000;11:279-292.
35. Wolta J, Kaun C, Breuss JM, et al. Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells. Lab Invest. 1999;79:427-438.
36. Van Belle E, Witzenbichler B, Chen D, et al, Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation. 1998;97:381-390.
37. Sodhi A, Montaner S, Miyazaki H, Gutkind JS. MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1α in ras V12 upregulation of VEGF. Biochem Biophys Res Commun. 2001;287:292-300.
38. Jiang BH, Zheng JZ, Masahiro A, Vogt PK. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci U S A. 2000;97:1749-1753.
39. Xin X, Yang S, Ingle G, et al. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol. 2001;158:1111-1120.
40. Prat M, Crepalki T, Gandino L, Giordano S, Longati P, Comoglio P. C-terminal truncated forms of met, the hepatocyte growth factor receptor. Mol Cell Biol. 1991;11:5954-5962.
41. Wajih N, Walter J, Sane DC. Vascular origin of a soluble truncated form of the hepatocyte growth factor receptor (c-met). Circ Res. 2002;90:46-52.